Targeting the BlyS/APRIL axis in neuro-Behçet disease: a rationale for telitacicept as a steroid-sparing strategy
Open Access
- 17 April 2026
- journal article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3825-3826
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Neuro-Behçet’s disease: an update of clinical diagnosis, biomarkers, and immunopathogenesisClinical and Experimental Immunology, 2025
- A multicenter, randomized, open‐label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravisEuropean Journal of Neurology, 2024
- Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trialAnnals of the Rheumatic Diseases, 2023
- Diagnosis and management of Neuro-Behçet’s disease: international consensus recommendationsJournal of Neurology, 2013
- Elevated BAFF Levels in the Cerebrospinal Fluid of Patients with Neuro‐Behçet’s Disease: BAFF is Correlated with Progressive Dementia and PsychosisScandinavian Journal of Immunology, 2012